Abstract
In early 1987 treatment of symptomatic HIV-infected patients was improved by the availability and licensing of the nucleoside analogue zidovudine (ZDV, AZT, Retrovir®) as the first anti-retroviral drug in most countries of the developed world. Although more compounds have become available since then, zidovudine remains a cornerstone of therapy for HIV infection. In most countries zidovudine monotherapy is still the first choice for HIV-infected patients who have become symptomatic or who have developed a CD4 lymphocyte count beneath 500/mm3.KeywordsHuman Immunodeficiency VirusHuman Immunodeficiency Virus TypeHuman Immunodeficiency Virus InfectionZidovudine TherapyMulticenter AIDS Cohort StudyThese keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
